Evaluating the role of Etravirine in the second-line antiretrovinal therapy after failing an initial non-nucleoside reverse transcriptase inhibitor-based regimen in a resource-limited setting

Current HIV Research

Volumn 6, Issue 5, 2008, Pages 474-476

  Sungkanuparph, Somnuek ^a,b   Manosuthi, Weerawat ^a   Kiertiburanakul, Sasisopin ^a   Piyavong, Bucha ^a   Chantratita, Wasun ^b  

^a MINISTRY OF PUBLIC HEALTH   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Antiretroviral therapy; Etravirine; HIV; Mutations; Resistance; TMC125

Indexed keywords

DIDANOSINE; EFAVIRENZ; ETRAVIRINE; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ADULT; ANTIVIRAL SUSCEPTIBILITY; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; DRUG TREATMENT FAILURE; FEMALE; GENE MUTATION; GENETIC ANALYSIS; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; RESOURCE ALLOCATION; REVIEW; TREATMENT DURATION;

ADULT; AMINO ACID SUBSTITUTION; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MUTATION, MISSENSE; PYRIDAZINES; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; SALVAGE THERAPY; TREATMENT OUTCOME; VIRAL LOAD;

EID: 53849116809     PISSN: 1570162X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016208785861230     Document Type: Review

References (13)

1. Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Piyavong B, Chumpathat N, Chantratita W. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails. Clin Infect Dis 2007; 44: 447-52.
2. Chetchotisakd P, Anunnatsiri S, Kiertiburanakul S, et al. High rate multiple drug resistances in HIV-infected patients failing nonnucleoside reverse transcriptase inhibitor regimens in Thailand, where subtype A/E is predominant. J Int Assoc Physicians AIDS Care (Chic III) 2006; 5: 152-6.
3. Marcelin AG, Jarrousse B, Derache A, et al. HIV drug resistance after the use of generic fixed-dose combination stavudine/lamivudine/ nevirapine as standard first-line regimen. AIDS 2007; 21: 2341-3.
4. Madruga JV, Cahn P, Grinsztejn B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007; 370: 29-38.
5. Lazzarin A, Campbell T, Clotet B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007; 370: 39-48.
6. Johnson VA, Brun-Vézinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: 2007. Top HIV Med 2007; 15: 119-25.
7. Picchio G, Vingerhoets J, Staes M, et al. Prevalence of TMC125 resistance-associated mutations in a large panel of clinical isolates. The 15th Conference on Retroviruses and Opportunistic Infections (CROI), Boston, Abstract 866: 2008.
8. Calmy A, Pinoges L, Szumilin E, Zachariah R, Ford N, Ferradini L; on behalf of Medecins Sans Frontieres. Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort. AIDS 2006; 20: 1163-9.
9. Ferradini L, Jeannin A, Pinoges L, et al. Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet 2006; 367: 1335-42.
10. Idigbe EO, Adewole TA, Eisen G, et al. Management of HIV-1 infection with a combination of nevirapine, stavudine, and lamivudine: a preliminary report on the Nigerian antiretroviral program. J Acquir Immune Defic Syndr 2005; 40: 65-9.
11. Ferrer E, Podzamczer D, Amedo K et al. Genotype and phenotype at baseline and at failure in human immunodeficiency virus-infected antiretroviral-naive patients in a randomized trial comparing zidovudine and lamivudine plus nelfinavir or nevirapine. J Infect Dis 2003; 187: 687-90.
12. Vidal C, Amedo M, Garcia F, et al. Genotypic and phenotypic resistance patterns in early-stage HIV-1-infected patients failing initial therapy with stavudine, didanosine and nevirapine. Antivir Ther 2002; 7: 283-7.
13. Vingerhoets I, Buelens A, Peeters; M, et al. Impact of baseline NNRTI mutations on the virological response to TMCl25 in the Phase III clinical trials DUET-1 and DUET-2. Antivir Ther 2007; 12: S34.